372 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Teva (TEVA) to Report Q3 Earnings: What's in the Cards? http://www.zacks.com/stock/news/332222/teva-teva-to-report-q3-earnings-whats-in-the-cards?cid=CS-ZC-FT-332222 Oct 29, 2018 - While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings http://www.zacks.com/stock/news/332054/5-drug-biotech-stocks-likely-to-beat-estimates-in-q3-earnings?cid=CS-ZC-FT-332054 Oct 26, 2018 - We take a look at a few stocks that might deliver an earnings beat when they report next week.
Why Earnings Season Could Be Great for Allergan (AGN) http://www.zacks.com/stock/news/331791/why-earnings-season-could-be-great-for-allergan-agn?cid=CS-ZC-FT-331791 Oct 26, 2018 - Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Glaxo (GSK) This Earnings Season? http://www.zacks.com/stock/news/331996/whats-in-the-cards-for-glaxo-gsk-this-earnings-season?cid=CS-ZC-FT-331996 Oct 26, 2018 - Glaxo's (GSK) is expected to see strong sales in its Vaccines business segment.
Universal Health Services (UHS) Q3 Earnings: A Beat in the Cards? http://www.zacks.com/stock/news/330838/universal-health-services-uhs-q3-earnings-a-beat-in-the-cards?cid=CS-ZC-FT-330838 Oct 24, 2018 - United Health's (UHS) third quarter is likely to gain from solid segmental performances and higher number of admissions.
Is a Beat in the Cards for Allergan (AGN) in Q3 Earnings? http://www.zacks.com/stock/news/330815/is-a-beat-in-the-cards-for-allergan-agn-in-q3-earnings?cid=CS-ZC-FT-330815 Oct 24, 2018 - While Allergan's (AGN) Q3 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.
What's in Store for Centene (CNC) This Earnings Season? http://www.zacks.com/stock/news/329257/whats-in-store-for-centene-cnc-this-earnings-season?cid=CS-ZC-FT-329257 Oct 18, 2018 - Centene's (CNC) third quarter should exhibit strong performances by its Government-backed and Medicaid businesses.
EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq http://www.zacks.com/stock/news/328751/eyepoint-eypt-gets-fda-approval-for-eye-therapy-yutiq?cid=CS-ZC-FT-328751 Oct 17, 2018 - EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.
Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes? http://www.zacks.com/stock/news/328547/can-allergans-key-drugs-solid-pipeline-abate-generic-woes?cid=CS-ZC-FT-328547 Oct 17, 2018 - Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.
Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara http://www.zacks.com/stock/news/326044/paratek-prtk-gets-fda-approval-for-nuzyra-and-seysara?cid=CS-ZC-FT-326044 Oct 03, 2018 - Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.

Pages: 1...678910111213141516...38

<<<Page 11>